60 Degrees Pharmaceuticals Set to Shine at Global Investment Event
60 Degrees Pharmaceuticals Set to Shine at Global Investment Event
Recently, 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a pioneering company dedicated to addressing vector-borne diseases through innovative medications, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. This significant event will be held at the Lotte New York Palace Hotel, providing a platform for companies to engage with investors and present their latest advancements.
Conference Participation Details
Dr. Geoff Dow, the CEO of 60 Degrees Pharmaceuticals, will take the stage on September 10, conducting a live presentation at 2:30 PM ET. The conference will also feature one-on-one meetings with company management, allowing potential investors to engage directly. Attendees can access these opportunities through the conference portal or by contacting the company directly via the investor relations contact shared below.
Exciting Live Webcast
For those unable to attend in person, a live webcast of the presentation will be available. Additionally, a replay will be accessible for approximately 90 days after the event on the 60 Degrees Pharmaceuticals investor page, ensuring that interested parties can catch up on the insights shared during the conference.
Company Overview
Founded in 2010, 60 Degrees Pharmaceuticals has carved a niche in the pharmaceutical sector with a focus on developing and commercializing novel treatments for vector-borne diseases. A standout achievement for the company was securing FDA approval for its leading product, ARAKODA® (tafenoquine), which is used for malaria prevention. Since its launch in 2018, ARAKODA has been available to patients in the United States and Australia.
The company emphasizes collaboration, often working alongside esteemed research and academic institutions both in the U.S. and Australia. With headquarters in Washington, D.C., and a subsidiary located in Australia, 60 Degrees Pharmaceuticals is positioning itself as a leader in combating vector-borne illnesses. Those looking to understand more about its mission and products can find comprehensive information on their official website.
Media inquiries can be directed to Sheila A. Burke at (484) 667-6330 or via email. For investor-related questions, Patrick Gaynes is the primary contact available for any inquiries.
Frequently Asked Questions
What is 60 Degrees Pharmaceuticals known for?
The company focuses on developing new medicines aimed at treating vector-borne diseases.
When will 60 Degrees Pharmaceuticals present at the investment conference?
Dr. Geoff Dow will present on September 10 at 2:30 PM ET during the H.C. Wainwright conference.
How can investors engage with 60 Degrees Pharmaceuticals at the event?
Investors can request one-on-one meetings through the conference portal or contact management directly.
What product has 60 Degrees Pharmaceuticals developed for malaria prevention?
The company's lead product for malaria prevention is ARAKODA® (tafenoquine), which received FDA approval in 2018.
Where is 60 Degrees Pharmaceuticals headquartered?
The company is headquartered in Washington, D.C., with a subsidiary in Australia.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
